Advantages and drawbacks of dexamethasone in glioblastoma multiforme. (April 2022)
- Record Type:
- Journal Article
- Title:
- Advantages and drawbacks of dexamethasone in glioblastoma multiforme. (April 2022)
- Main Title:
- Advantages and drawbacks of dexamethasone in glioblastoma multiforme
- Authors:
- Afshari, Amir R.
Sanati, Mehdi
Aminyavari, Samaneh
Shakeri, Farzaneh
Bibak, Bahram
Keshavarzi, Zakieh
Soukhtanloo, Mohammad
Jalili-Nik, Mohammad
Sadeghi, Mohammad Montazami
Mollazadeh, Hamid
Johnston, Thomas P.
Sahebkar, Amirhossein - Abstract:
- Abstract: The most widespread, malignant, and deadliest type of glial tumor is glioblastoma multiforme (GBM). Despite radiation, chemotherapy, and radical surgery, the median survival of afflicted individuals is about 12 months. Unfortunately, existing therapeutic interventions are abysmal. Dexamethasone (Dex), a synthetic glucocorticoid, has been used for many years to treat brain edema and inflammation caused by GBM. Several investigations have recently shown that Dex also exerts antitumoral effects against GBM. On the other hand, more recent disputed findings have questioned the long-held dogma of Dex treatment for GBM. Unfortunately, steroids are associated with various undesirable side effects, including severe immunosuppression and metabolic changes like hyperglycemia, which may impair the survival of GBM patients. Current ideas and concerns about Dex's effects on GBM cerebral edema, cell proliferation, migration, and its clinical outcomes were investigated in this study. Highlights: Dexamethasone has been used for many years to treat brain edema and inflammation caused by GBM. Several investigations have shown that dexamethasone also exerts antitumoral effects against GBM. Unfortunately, steroids are associated with various undesirable side effects. Herein, we review pre-clinical and clinical applications of Dexamethasone in GBM.
- Is Part Of:
- Critical reviews in oncology/hematology. Volume 172(2022)
- Journal:
- Critical reviews in oncology/hematology
- Issue:
- Volume 172(2022)
- Issue Display:
- Volume 172, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 172
- Issue:
- 2022
- Issue Sort Value:
- 2022-0172-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-04
- Subjects:
- Glioblastoma multiforme -- Dexamethasone -- Cerebral edema -- Inflammation -- Proliferation
Oncology -- Periodicals
Hematology -- Periodicals
616.994 - Journal URLs:
- http://www.sciencedirect.com/science/journal/10408428 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.critrevonc.2022.103625 ↗
- Languages:
- English
- ISSNs:
- 1040-8428
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3487.479000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21292.xml